Synvivia

Synvivia discovered genuine demand when biopharmaceutical manufacturers began unprompted conversations about their cell culture bottlenecks. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Rather than pitching their chemical control platform, the founders heard repeated complaints from production teams struggling with inconsistent yields and batch failures—problems costing millions annually. They measured real interest by tracking how many manufacturers requested technical deep-dives and shared proprietary production data, a significant commitment in an industry protective of processes. Early traction emerged when three contract manufacturers independently ran pilot batches using Synvivia's approach, each reporting 15-20% yield improvements within weeks. The decisive evidence came when these manufacturers requested formal partnerships before any commercial terms were discussed, and when they began allocating dedicated resources to integration rather than treating it as a side project. Manufacturing teams' willingness to disrupt established workflows and share confidential data proved they weren't merely interested in theory—they faced urgent, expensive problems that Synvivia's platform actually solved.